Nitrosothiol signaling in anoikis resistance and cancer metastasis

Forum on Immunopathological Diseases and Therapeutics

Volumn 3, Issue 2, 2012, Pages 141-154

  Luanpitpong, Sudjit ^a   Iyer, Anand Krishnan V ^a   Azad, Neelam ^a   Wang, Liying ^b   Rojanasakul, Yon ^a,c  

^a HAMPTON UNIVERSITY   (United States)

^b NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

^c WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Anoikis; Cancer; Invasion; Metastasis; Nitric oxide; S nitrosylation

Indexed keywords

APOPTOSIS REGULATORY PROTEIN; CAVEOLIN; FLICE INHIBITORY PROTEIN; GELATINASE B; NITRIC OXIDE; NITROSOTHIOL; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN TYROSINE KINASE; RAS PROTEIN; THIOL; UNCLASSIFIED DRUG;

ANOIKIS; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL INVASION; CELL MOTILITY; CELL SURVIVAL; COLORECTAL CANCER; CONFERENCE PAPER; HUMAN; LUNG SMALL CELL CANCER; METASTASIS; NITROSYLATION; OSTEOSARCOMA; PANCREAS CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

EID: 84872350678     PISSN: 21518017     EISSN: 21518025     Source Type: Journal    
DOI: 10.1615/ForumImmunDisTher.2012006115     Document Type: Conference Paper

References (64)

1. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526. (Pubitemid 17085822)
2. Knowles RG. Nitric oxide synthases. Biochem Soc Trans. 1996;24:875-878. (Pubitemid 26306316)
3. Thomsen LL, Miles DW, Happerfield L, Bobrow LG, Knowles RG, Moncada S. Nitric oxide synthase activity in human breast cancer. Br J Cancer. 1995;72:41-44.
4. Puhukka A, Kinnula V, Napankangas U, Saily M, Koistinen P, Paakko P, Soini Y. High expression of nitric oxide synthases is a favorable prognostic sign in non-small cell lung carcinoma. APMIS. 2003;111:1137-1146. (Pubitemid 38091254)
5. Bakshi A, Nag TC, Wadhwa S, Mahapatra AK, Sarkar C. The expression of nitric oxide synthases in human brain tumours and peritumoral areas. J Neuro Sci. 1998;155:196-203. (Pubitemid 28139021)
6. Fukumura D, Kashiwagi S, Jain RK. The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006;6:521-534. (Pubitemid 43980541)
7. Tse GM, Wong FC, Tsang AK, Lee CS, Lui PC, Lo AW, Law BK, Scolyer RA, Karim RZ, Putti TC. Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phallodes tumour. J Clin Pathol. 2005;58:600-604. (Pubitemid 40814019)
8. Mocellin S, Bronte V, Nitti D. Nitric oxide a double edged sword in cancer biology: searching for therapeutic opportunities. Med Res Rev. 2007;27:317-352. (Pubitemid 46668937)
9. Heigold S, Sers C, Bechtel W, Ivanovas B, Schafer R, Bauer G. Nitric oxide mediates apoptosis induction selective in transformed fibroblasts compared to non-transformed fibroblasts. Carcinogenesis. 2002;23:929-941. (Pubitemid 34752948)
10. Ridnour LA, Thomas DD, Donzell D, Espey MG, Roberts DD, Wink DA, Isenberg JS. The biphasic nature of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2001;2:149-156.
11. Cheng R, Glynn S, Flores-Santana W, Switzer C, Ridnour L, Wink DA. Chapter 5 - Nitric oxide and redox inflammation in cancer. Adv Mol Toxicol. 2010;4:157-182.
12. Iyer AKV, Azad N, Wang L, Rojanasakul Y. S-nitrosylation. How cancer cells say NO to cell death. In: Benjamin B, editor. Nitric Oxide (NO) and Cancer, Prognosis, Prevention and Therapy. New York: Springer; 2010. p. 3-20.
13. Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA. The chemical biology of nitric oxide: implications in cellular signaling. Free Radi cBiol Med. 2008;45:18-31.
14. Leon L, Jeannin JF, Bettaieb A. Post-translational modifications induced by nitric oxide (NO): implications in cancer cells apoptosis. Nitric Oxide. 2008;19:77-83.
15. Hess DT, Matsumoto A, Kim SO, Marshall HE, Stamler JS. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol. 2005;6:150-166. (Pubitemid 40215810)
16. Stamler JS, Lamas S, Fang FC. Nitrosylation. The prototypic redox-based signaling mechanism. Cell. 2001;78:931-936.
17. Lane P, Hao G, Gross SS. S-nitrosylation is emerging as a specific and fundamental posttranslational protein modification: head-to-head comparison with O-phosphorylation. Sci STKE. 2001;86:RE1.
18. Chaffer CL, Weinberg RA. A perspective on cancer cell metastasis. Science. 2011;331:1559-1564.
19. Fidler I. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003;3:453-458. (Pubitemid 37328849)
20. Frisch SM, Screaton RA. Anoikis mechanisms. Curr Opin Cell Biol. 2002;14:563-568.
21. Simpson CD, Anyiwe K, Schimmer AD. Anoikis resistance and tumor metastasis. Cancer Lett. 2008;272:177-185.
22. Hanahan D, Weiberg RA. The hallmarks of cancer. Cell. 2000;100:57-70. (Pubitemid 30046295)
23. Sakamoto S, Kyprianou N. Targeting anoikis resistance in prostate cancer metastasis. Mol Aspects Med. 2010;31:205-214.
24. Chen YJ, Kuo CD, Tsai YM, Yu CC, Wang GS, Liao HF. Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs. 2008;19:55-64.
25. Dufour G, Demers MJ, Gagne D, Dydensborg AB, Teller IC, Bouchard B, Degongre I, Beaulieu JF, Cheng JQ, Fujita N, Tsuruo T, Vallee K, Vachon PH. Human intestinal epithelial cell survival and anoikis. Differentiation state-distinct regulation and roles of protein kinase B/Akt isoforms. J Biol Chem. 2004;279:44113-44122. (Pubitemid 39403045)
26. Collins NL, Reginato MJ, Paulus JK, Sgroi DC, Joshua L, Brugge JS. G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression. Mol Cell Biol. 2005;25:5282-5291. (Pubitemid 40781124)
27. Yang G, Truong L, Timme TL, Ren C, Wheeler TM, Park SH, Nasu Y, Bangma CH, Kattan MW, Scardino PT, Thompson TC. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res. 1998;4:1873-1880. (Pubitemid 28369170)
28. Ho CC, Huang PH, Huang HY, Chen YH, Yang PC, Hsu SM. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am J Pathol. 2002;161:1647-1656.
29. Patlolla JM, Swamy MV, Raju J, Rao CV. Overexpression of Caveolin-1 in experimental colon adenocarcinomas and human colon cancer cell lines. Oncol Rep. 2004;115:719-724.
30. Ravid D, Maor S, Werner H, Liscovitch M. Caveolin-1 inhibits anoikis and promotes survival signaling in cancer cells. Adv Enzyme Regul. 2006;46:163-175. (Pubitemid 44301363)
31. Ravid D, Moar S, Werner H, Liscovitch M. Caveolin-1 inhibits cell detachment-induced p53 activation and anoikis by upregulation of insulin-like growth factor-1 receptor and signaling. Oncogene. 2005;17:1338-1347. (Pubitemid 40343114)
32. Li L, Ren CH, Tahir SA, Ren C, Thompson TC. Caveolin-1 maintains activated Akt in prostate cancer cells through scaffolding domain binding site interactions with and inhibition of serine/threonine protein phosphatases PP1 and PP2A. Mol Cell Biol. 2003;23:9389-9404. (Pubitemid 37499824)
33. Chunhacha P, Pongrakananon V, Rojanasakul Y, Chanvorachote P. Caveolin-1 regulates Mcl-1 stability and anoikis in lung carcinoma cells. Am J Physiol Cell Physiol. 2012;302:C1284-C1292.
34. Chanvorachote P, Nimmannit U, Lu Y, Talbott S, Jiang BH, Rojanasakul Y. Nitric oxide regulates lung carcinoma cell anoikis through inhibition of ubiquitin-proteasomal degradation of caveolin-1. J Biol Chem. 2009;284:28476-28484.
35. Guicciardi ME, Gores GJ. Life and death by death receptors. FASEB J. 2009;23:1625-1637.
36. Kim YN, Koo KH, Sung JY, Yun UJ, Kim H. Anoikis resistance: an essential prerequisite for tumor metastasis. Int J Cell Biol. 2012;2012:306879.
37. Mawji IA, Simpson CD, Hurren R, Gronda M, Williams MA, Filmus J, Jonkman J, Da Costa RS, Wilson BC, Thomas MP, Reed JC, Glinsky GV, Schimmer AD. Critical role for Fas-associated death domain-like interleukin-1-converting enzyme-like inhibitory protein in anoikis resistance and distant tumor formation. J Natl Cancer Inst. 2007;99:811-822. (Pubitemid 47073526)
38. Dingsheng L, Jie F, Weishan C. Bcl-2 and caspase-8 related anoikis resistance in human osteosarcoma MG-63 cells. Cell Biol Int. 2008;32:1199-1206.
39. Joseph MG, Melinda MM, Tawnya LB, Subbulakshmi V, Richard JB. ERK/BCL-2 Pathway in the resistance of pancreatic cancer to anoikis. J Surg Res. 2009;152:18-25.
40. Chanvorachote P, Nimmannit U, Wang L, Stehlik C, Lu B, Azad N, Rojanasakul Y. Nitric oxide negatively regulates Fas CD95-induced apoptosis through inhibition of ubiquitin-proteasome-mediated degradation of FLICE-inhibitory protein. J Biol Chem. 2005;280:42044-42050. (Pubitemid 43023173)
41. Chanvorachote P, Nimmannit U, Stehlik C, Wang L, Jiang BH, Ongpipatanakul B, Rojanasakul Y. Nitric oxide regulates cell sensitivity to cisplatin-induced apoptosis through S-nitrosylation and inhibition of Bcl-2 ubiquitination. Cancer Res. 2006;66:6353-6360.
42. Azad N, Vallyathan V, Wang L,Tantishaiyakul V, Stehlik C, Leonard SS, Rojanasakul Y. S-nitrosylation of Bcl-2 inhibits its ubiquitin-proteasomal degradation. A novel antiapoptotic mechanism that suppresses apoptosis. J Biol Chem. 2006;281:34124-34134. (Pubitemid 46036621)
43. Iyer AKV, Azad N, Wang L, Rojanasakul Y. Role of S-nitrosylation in apoptosis resistance and carcinogenesis. Nitric Oxide. 2008;19:146-151.
44. Pongrakhananon V, Nimmannit U, Luanpitpong S, Rojanasakul Y, Chanvorachote P. Curcumin sensitizes non-small-cell lung cancer anoikis through reactive oxygen speciesmediated Bcl-2 downregulation. Apoptosis. 2010;15:574-585.
45. Khwaja A, Rodriguez-Viciana P, Wennstrom S. Warne PH, Downward J. Matrix adhesion and Ras transformation both activate a phosphoinoistide 3-OH kinase and protein kinase B/Akt cellular survival pathway. EMBO J. 1997;16:2783-2793. (Pubitemid 27226215)
46. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11:289-301.
47. Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Res. 2009;69:2875-2883.
48. Kwak YD, Ma T, Diao S, Zhang X, Chen Y, Hsu J, Lipton SA, Masliash E, Xu H, Liao FF. NO signaling and S-nitrosylation regulate PTEN inhibition in neurodegeneration. Mol Neurodegener. 2010;5:49.
49. Bravo-Cordero JJ, Hodgson L, Condeelis J. Directed cell invasion and migration during metastasis. Curr Opin Cell Biol. 2012;24:277-283.
50. Luanpitpong S, Talbott S, Rojanasakul Y, Nimmannit U, Pongrakhananon V, Wang L, Chanvorachote P. Regulation of lung cancer cell migration and invasion by reactive oxygen species and caveolin-1. J Biol Chem. 2010;285:38832-38840.
51. Giannoni E, Buricchi B, Raugei G, Ramponi G, Chiarugi P. Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol. 2005;25:6391-6403. (Pubitemid 41023216)
52. Irby RB, Yeatman TJ. Role of Src expression and activation in human cancer. Oncogene. 2000;19:5636-5642.
53. Akhand AA, Pu M, Senga T, Kato M, Suzuki H, Miyata T, Hamaguchi M, Nakashima I. Nitric oxide controls Src kinase activity through a sulfhydyl group modification-mediated Tyr-527-independent and Tyr-416-linked mechanism. J Biol Chem. 1999;274:25821-25826.
54. Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, Hamaguchi M. S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem. 2010;285:3806-3814.
55. Campbell PM, Der CJ. Oncogenic Ras and its role in tumor cell invasion and metastasis. Sem Cancer Biol. 2004;14:105-114. (Pubitemid 38234752)
56. Kashatus DF, Counter CM. A role for eNOS in oncogenic Ras-driven cancer. In: Bonvanida B, ed. Nitric Oxide (NO) and Cancer: Prognosis, Prevention, and Therapy (Cancer Drug Delivery and Development). New York: Springer. p. 23-38. 2010.
57. Lim KH, Ancrile BB, Kashatus DF, Counter CM. Tumor maintenance is mediated by eNOS. Nature. 2008;452:646-649.
58. Raines K, Cao GL, Lee EK, Rosen GM, Shapiro P. Neuronal nitric oxide synthase-induced S-nitrosylation of H-Ras inhibits calcium iono-phore-mediated extracellular-signal-regulated kinase activity. Biochem J. 2006;397:329-336. (Pubitemid 44076903)
59. Iyer AK, Azad N, Talbot S, Stehlik C, Lu B, Wang L, Rojanasakul Y. Antioxidant c-FLIP inhibits Fas ligand-induced NF-κB activation in a phosphatidylinositol 3-kinase/Akt-dependent manner. J Immunol. 2011;187:3256-3266.
60. Shim E, Lee YS, Kim HY, Jeoung D. Downregulation of c-FLIP increases reactive oxygen species, induces phosphorylation of serine/threonine kinase Akt, and impairs motility of cancer cells. Biotechnol Lett. 2007;29:141-147. (Pubitemid 44950170)
61. Chen JH, Lin HH, Chiang TA, Hsu JD, Ho HH, Lee YC, Wang CJ. Gaseous nitrogen oxide promotes human lung cancer cell line A549 migration, invasion, and metastasis via iNOS-mediated MMP-2 production. Toxicol Sci. 2008;106:364-375.
62. Iwakiri Y, Satoh A, Chatterjee S, Toomre DK, Chalouni CM, Fulton D, Groszmann RJ, Shah VH, Sessa WC. Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking. Proc Natl Acad Sci U S A. 2006;103:19777-19782. (Pubitemid 46037507)
63. Roomi MW, Monterrey JC, Kalinovsky T, Rath M, Niedzwiecki A. Patterns of MMP-2 and MMP-9 expression. Oncol Rep. 2009;21:1323-1333.
64. Wang Z. Protein S-nitrosylation and cancer. Cancer Lett. 2012;320:123-129.